Annexin (Q2 Review): Further data expected in H2 - Redeye

Redeye returns with a research update following Annexin's Q2 report. We continue to see good progress from the NEXUS-study and expect more update during the autumn and winter. We reiterate our fundamental DCF valuation but following Redeye's new valuation approach, we set our new Fair value to SEK61 per share, which also takes peer valuation into consideration; the stock screens as Cheap.

Länk till analysen i sin helhet: https://www.redeye.se/research/1181246/annexin-q2-review-further-data-expected-in-h2?utm_source=finwire&utm_medium=RSS